KR20180070708A - 상처 치유를 위한 플라스미노겐 투여 요법 - Google Patents
상처 치유를 위한 플라스미노겐 투여 요법 Download PDFInfo
- Publication number
- KR20180070708A KR20180070708A KR1020187016082A KR20187016082A KR20180070708A KR 20180070708 A KR20180070708 A KR 20180070708A KR 1020187016082 A KR1020187016082 A KR 1020187016082A KR 20187016082 A KR20187016082 A KR 20187016082A KR 20180070708 A KR20180070708 A KR 20180070708A
- Authority
- KR
- South Korea
- Prior art keywords
- wound
- plasminogen
- biologically active
- dose
- active variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000013566 Plasminogen Human genes 0.000 title claims abstract description 193
- 108010051456 Plasminogen Proteins 0.000 title claims abstract description 193
- 230000029663 wound healing Effects 0.000 title claims abstract description 22
- 238000002560 therapeutic procedure Methods 0.000 title description 32
- 238000000034 method Methods 0.000 claims abstract description 90
- 239000003814 drug Substances 0.000 claims abstract description 63
- 238000011200 topical administration Methods 0.000 claims abstract description 30
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 206010052428 Wound Diseases 0.000 claims description 292
- 208000027418 Wounds and injury Diseases 0.000 claims description 281
- 230000001684 chronic effect Effects 0.000 claims description 34
- 208000025865 Ulcer Diseases 0.000 claims description 32
- 231100000397 ulcer Toxicity 0.000 claims description 31
- 239000000243 solution Substances 0.000 claims description 23
- 238000002347 injection Methods 0.000 claims description 19
- 239000007924 injection Substances 0.000 claims description 19
- 210000003454 tympanic membrane Anatomy 0.000 claims description 18
- 238000007920 subcutaneous administration Methods 0.000 claims description 17
- 206010012601 diabetes mellitus Diseases 0.000 claims description 16
- 241000282414 Homo sapiens Species 0.000 claims description 15
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 15
- 230000002829 reductive effect Effects 0.000 claims description 15
- 208000008960 Diabetic foot Diseases 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 13
- 230000035876 healing Effects 0.000 claims description 13
- 230000001154 acute effect Effects 0.000 claims description 12
- 210000003462 vein Anatomy 0.000 claims description 11
- 206010011985 Decubitus ulcer Diseases 0.000 claims description 10
- 230000003902 lesion Effects 0.000 claims description 10
- 238000007906 compression Methods 0.000 claims description 9
- 230000006835 compression Effects 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 230000001737 promoting effect Effects 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 8
- 238000007918 intramuscular administration Methods 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 6
- 210000003141 lower extremity Anatomy 0.000 claims description 6
- 210000004204 blood vessel Anatomy 0.000 claims description 5
- 238000011282 treatment Methods 0.000 abstract description 86
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 210000002414 leg Anatomy 0.000 description 16
- 210000003491 skin Anatomy 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 14
- 210000002683 foot Anatomy 0.000 description 11
- 208000003790 Foot Ulcer Diseases 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 9
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 101000605403 Homo sapiens Plasminogen Proteins 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 229940012957 plasmin Drugs 0.000 description 8
- 206010040943 Skin Ulcer Diseases 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 108010087750 lysyl-plasminogen Proteins 0.000 description 7
- 108010039627 Aprotinin Proteins 0.000 description 6
- 206010010741 Conjunctivitis Diseases 0.000 description 6
- 102000009123 Fibrin Human genes 0.000 description 6
- 108010073385 Fibrin Proteins 0.000 description 6
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 6
- 229960004405 aprotinin Drugs 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229950003499 fibrin Drugs 0.000 description 6
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 102100033571 Tissue-type plasminogen activator Human genes 0.000 description 5
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 206010010356 Congenital anomaly Diseases 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 206010042674 Swelling Diseases 0.000 description 4
- 208000000558 Varicose Ulcer Diseases 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 210000000613 ear canal Anatomy 0.000 description 3
- 210000000959 ear middle Anatomy 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 102400000069 Activation peptide Human genes 0.000 description 2
- 101800001401 Activation peptide Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000005230 Leg Ulcer Diseases 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 206010045210 Tympanic Membrane Perforation Diseases 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000009692 acute damage Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000002266 amputation Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 238000005549 size reduction Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- -1 that is Proteins 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000007838 tissue remodeling Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 208000035620 Eye penetration Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 208000018982 Leg injury Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025282 Lymphoedema Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000283080 Proboscidea <mammal> Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 229940122055 Serine protease inhibitor Drugs 0.000 description 1
- 101710102218 Serine protease inhibitor Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 108700036309 Type I Plasminogen Deficiency Proteins 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 201000005547 chronic conjunctivitis Diseases 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 210000001752 female genitalia Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000001255 hallux Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 206010071570 ligneous conjunctivitis Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000002502 lymphedema Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 108010049112 miniplasminogen Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 230000033885 plasminogen activation Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562253352P | 2015-11-10 | 2015-11-10 | |
| US62/253,352 | 2015-11-10 | ||
| PCT/IB2016/001606 WO2017081529A1 (en) | 2015-11-10 | 2016-11-10 | Plasminogen dosage regimen for wound healing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180070708A true KR20180070708A (ko) | 2018-06-26 |
Family
ID=57485826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187016082A Withdrawn KR20180070708A (ko) | 2015-11-10 | 2016-11-10 | 상처 치유를 위한 플라스미노겐 투여 요법 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20180326023A1 (https=) |
| EP (1) | EP3373957A1 (https=) |
| JP (1) | JP2018534306A (https=) |
| KR (1) | KR20180070708A (https=) |
| CN (1) | CN108289934A (https=) |
| AU (1) | AU2016352183A1 (https=) |
| BR (1) | BR112018009476A8 (https=) |
| CA (1) | CA3004509A1 (https=) |
| IL (1) | IL259172A (https=) |
| MX (1) | MX2018005876A (https=) |
| RU (1) | RU2018121234A (https=) |
| TW (1) | TW201722464A (https=) |
| WO (1) | WO2017081529A1 (https=) |
| ZA (1) | ZA201803010B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI868051B (zh) * | 2017-06-23 | 2025-01-01 | 美商波麥堤克生物治療股份有限公司 | 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 |
| CN111050763B (zh) * | 2017-12-26 | 2024-10-11 | 福冈大太朗 | 用于増毛、头皮或皮肤的改质、创伤治愈、骨形成促进或毛发的改质的药物组合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7067492B2 (en) * | 2001-09-06 | 2006-06-27 | Omnio Ab | Method of promoting healing of a tympanic membrane perforation |
| GB0509438D0 (en) | 2005-05-09 | 2005-06-15 | Prometic Biosciences Ltd | Affinity adsorbets for fibrinogen |
| WO2009093970A1 (en) * | 2008-01-22 | 2009-07-30 | Omnio Healer Ab | Method of improving wound healing |
| JP6085568B2 (ja) | 2011-01-05 | 2017-02-22 | スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ | プラスミノーゲンおよびプラスミンの変異体 |
| US9644196B2 (en) | 2011-08-12 | 2017-05-09 | Thrombogenics Nv | Plasminogen and plasmin variants |
| PY1577621A (es) * | 2014-12-19 | 2017-10-02 | Prometic Biotherapeutics Inc | Composicion farmaceutica que comprende plasminogeno y uso para el mismo |
| TWI801331B (zh) * | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
-
2016
- 2016-11-09 TW TW105136489A patent/TW201722464A/zh unknown
- 2016-11-10 US US15/774,155 patent/US20180326023A1/en not_active Abandoned
- 2016-11-10 WO PCT/IB2016/001606 patent/WO2017081529A1/en not_active Ceased
- 2016-11-10 JP JP2018524824A patent/JP2018534306A/ja active Pending
- 2016-11-10 RU RU2018121234A patent/RU2018121234A/ru not_active Application Discontinuation
- 2016-11-10 MX MX2018005876A patent/MX2018005876A/es unknown
- 2016-11-10 KR KR1020187016082A patent/KR20180070708A/ko not_active Withdrawn
- 2016-11-10 CA CA3004509A patent/CA3004509A1/en not_active Abandoned
- 2016-11-10 EP EP16806278.4A patent/EP3373957A1/en not_active Withdrawn
- 2016-11-10 BR BR112018009476A patent/BR112018009476A8/pt not_active Application Discontinuation
- 2016-11-10 CN CN201680065255.3A patent/CN108289934A/zh active Pending
- 2016-11-10 AU AU2016352183A patent/AU2016352183A1/en not_active Abandoned
-
2018
- 2018-05-06 IL IL259172A patent/IL259172A/en unknown
- 2018-05-08 ZA ZA2018/03010A patent/ZA201803010B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017081529A1 (en) | 2017-05-18 |
| ZA201803010B (en) | 2019-07-31 |
| JP2018534306A (ja) | 2018-11-22 |
| BR112018009476A2 (pt) | 2018-11-13 |
| US20180326023A1 (en) | 2018-11-15 |
| CA3004509A1 (en) | 2017-05-18 |
| AU2016352183A1 (en) | 2018-06-28 |
| IL259172A (en) | 2018-06-28 |
| MX2018005876A (es) | 2018-11-09 |
| EP3373957A1 (en) | 2018-09-19 |
| RU2018121234A3 (https=) | 2020-03-12 |
| RU2018121234A (ru) | 2019-12-13 |
| BR112018009476A8 (pt) | 2019-02-26 |
| TW201722464A (zh) | 2017-07-01 |
| CN108289934A (zh) | 2018-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101706549B1 (ko) | 히알루로니다제를 포함하는 국소지방 제거용 주사제 조성물 | |
| KR101534468B1 (ko) | 당뇨병성 궤양 치료를 위한 약제제조를 위한 약학 조성물의 용도 | |
| KR100795654B1 (ko) | 당뇨성 발 절단 예방을 위한 표피성장인자 함유 약제학적조성물의 용도 | |
| Ranjbar | Overview of diabetic foot; novel treatments in diabetic foot ulcer | |
| US20140044667A1 (en) | Healing composition for topical application | |
| Crotty et al. | Ulcerative lichen planus: follow-up of surgical excision and grafting | |
| Liu et al. | Experimental study on the effect of chrysin on skin injury induced by amiodarone extravasation in rats | |
| KR20180070708A (ko) | 상처 치유를 위한 플라스미노겐 투여 요법 | |
| US7374772B2 (en) | Topical antifungal treatment | |
| RU2734159C1 (ru) | Фармацевтическая композиция для лечения болевого синдрома в стопе, включающая ботулинический токсин и гиалуроновую кислоту, и способ лечения болевого синдрома в стопе с ее использованием | |
| US10960011B2 (en) | Compositions for the treatment of ischemic ulcers and stretch marks | |
| US20230181661A1 (en) | Mushroom-containing chinese medicine compound composition for keloid scar tissue and application thereof | |
| Upadhyay et al. | An Overview on Underlying Concepts and Mechanisms of Wound Healing | |
| US12521392B2 (en) | Methods and compositions for promoting wound healing in a subject suffering from ectodermal dysplasias | |
| Yoon et al. | Treatment of scleroderma skin ulcers using becaplermin gel and hydrocolloid membrane | |
| RU2539385C2 (ru) | Способ лечения синдрома диабетической стопы | |
| CN108635362A (zh) | 一种治疗糖尿病足的药物组合物 | |
| Wynn et al. | Case Report: Wound Care of a Diabetic Foot Ulcer | |
| Zambre et al. | AYURVEDIC TREATMENT MODALITIES OF DEEP VEIN THROMBOSIS: A CASE STUDY | |
| Girase et al. | Randomized Controlled Clinical Trial to Check the Efficacy of Agnikarma (Thermal Cauterization) with Panchdhatu Shalaka Versus Surgical Excision in the Management of Kadara (Corn) | |
| Gayathridevi et al. | Effectiveness of Siddha Formulation Chitramoola Kuligai (CMK Tablet) In Treatment of Viranangal (Ulcers)–A Case Study of Two | |
| Alam et al. | Non-healing Ulcer Treated with Unani Formulation Zaroor-e-Qaw: A Case Report | |
| BISWAS | MANAGEMENT OF SNAKE BITE | |
| Rosenberg | A New Method for Treating Slow-healing Wounds | |
| KR20230136597A (ko) | 상처 치료를 위한 조성물들 및 방법들 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20180607 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination |